Narcolepsy: update on etiology, clinical features and treatment

被引：0

作者：

Pabon, R. M. ^{[1
]}

Garcia de Gurtubay, I. ^{[1
]}

Morales, G. ^{[1
]}

Urriza, J. ^{[1
]}

Imirizaldu, L. ^{[1
]}

Ramos-Argueelles, F. ^{[1
]}

机构：

[1] Hosp Virgen Camino, Serv Neurofisiol Clin, Pamplona 31008, Spain

来源：

ANALES DEL SISTEMA SANITARIO DE NAVARRA | 2010年 / 33卷 / 02期

关键词：

Cataplexy; Diagnosis; Narcolepsy; Treatment; Sodium oxybate; PRACTICE PARAMETERS; EFNS GUIDELINES; DIAGNOSIS; ONSET; MANAGEMENT; PEPTIDES; OREXIN;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Narcolepsy is a disease that involves an alteration in the generation and organisation of sleep. The main symptoms are excessive daytime sleepiness and cataplexy, followed by hypnagogic hallucinations, sleep paralysis and disrupted nocturnal sleep. The prevalence of typical narcolepsy oscillates between 25-50: 100.000 in general. Recently there has been a peak incidence in patients born in the month of March. According to the new classification, the Multiple Sleep Latency Test (MSLT) is mandatory for diagnosing narcolepsy without cataplexy, and advisable for diagnosing narcolepsy with cataplexy. Until now, the attempt has been made to control each symptom by its own specific treatment. At present, new American and European treatment guidelines propose new drugs that act on all the symptoms. The application of new criteria of diagnosis and treatment has improved the diagnosis, giving better options of treatment.

引用

页码：191 / 201

页数：11

共 31 条

[1]

[Anonymous], 2005, INT CLASSIFICATION S

[2] Health-related quality of life effects of modafinil for treatment of narcolepsy [J].

Beusterien, KM ;

Rogers, AE ;

Walsleben, JA ;

Emsellem, HA ;

Reblando, JA ;

Wang, LX ;

Goswami, M ;

Steinwald, B .

SLEEP, 1999, 22 (06) :757-765

[3] EFNS guidelines on management of narcolepsy [J].

Billiard, M. ;

Bassetti, C. ;

Dauvilliers, Y. ;

Dolenc-Groselj, L. ;

Lammers, G. J. ;

Mayer, G. ;

Pollmacher, T. ;

Reading, P. ;

Sonka, K. .

EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (10) :1035-1048

[4]

Billiard M, 2003, SLEEP PHYSL INVESTIG, P403

[5] Month of birth as a risk factor for narcolepsy [J].

Dauvilliers, Y ;

Carlander, B ;

Molinari, N ;

Desautels, A ;

Okun, M ;

Tafti, M ;

Montiplaisir, J ;

Mignot, E ;

Billiard, M .

SLEEP, 2003, 26 (06) :663-665

[6] Age at onset of narcolepsy in two large populations of patients in France and Quebec [J].

Dauvilliers, Y ;

Montplaisir, J ;

Molinari, N ;

Carlander, B ;

Ondze, B ;

Besset, A ;

Billiard, M .

NEUROLOGY, 2001, 57 (11) :2029-2033

[7] The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity [J].

De Lecea, L ;

Kilduff, TS ;

Peyron, C ;

Gao, XB ;

Foye, PE ;

Danielson, PE ;

Fukuhara, C ;

Battenberg, ELF ;

Gautvik, VT ;

Bartlett, FS ;

Frankel, WN ;

van den Pol, AN ;

Bloom, FE ;

Gautvik, KM ;

Sutcliffe, JG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :322-327

[8]

DEL CIDPELLITERO, 2007, REV NEUROLOGIA, V45, P482

[9] The socioeconomic impact of narcolepsy [J].

Dodel, R ;

Peter, H ;

Walbert, T ;

Spottke, A ;

Noelker, C ;

Berger, K ;

Siebert, U ;

Oertel, WH ;

Kesper, K ;

Becker, HF ;

Mayer, G .

SLEEP, 2004, 27 (06) :1123-1128

[10]

Eguía VM, 2007, AN SIST SANIT NAVAR, V30, P53, DOI 10.4321/s1137-66272007000200005

← 1 2 3 4 →